Clinical trials: Essential Hypertension.
Hypertension, Congestive Heart Failure
To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
To compare and evaluate the efficacy and safety of Candemore tab. versus Atacand tab. on blood pressure in patients with hypertension diagnosed congestive heart failure
- Trial name
- CANTABILE (NCT01682564)
- Testing
- Candemore tablet, Atacand tablet
- Where
- 14 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension
This is a Phase 4, prospective, multi-centric and randomized controlled study to compare the effects of bisoprolol and atenolol on resting heart rate (RHR) and sympathetic nervous system's (SNS) activity in subjects with…
- Trial name
- NCT01251146
- Testing
- Bisoprolol, Atenolol
- Where
- 2 sites in China
- Volunteers
- 177 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Essential Hypertension
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Perindopril Erbumine 8 mg tablets under fasting conditions.
- Trial name
- NCT01012687
- Testing
- perindopril erbumine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Hypertension, Left Ventricle Hypertrophy
ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling
The purpose of this study is to assess efficacy of aliskiren for reducing circulating levels of biomarkers of left ventricular (LV) remodeling associated with LV hypertrophy (LVH) in hypertensive patients.
- Trial name
- ALLMARK (NCT01176032)
- Testing
- Aliskiren, Losartan, Amlodipine
- Where
- 25 sites in Spain
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT07421414
- Testing
- BR1015-A, BR1015-3, BR1015-2
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
- Trial name
- NCT07660796
- Testing
- HCP1803-3, HCP1803-4, RLD2001-1
- Where
- South Korea
- Volunteers
- 256 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension, Carotid Plaque
The Confirmatory Olmesartan Plaque Regression Study
Effect of olmesartan medoxomil (20-40 mg) on plaque regression in hypertensive patients with carotid atherosclerosis.
- Trial name
- CONFIRM (NCT01132768)
- Testing
- Atenolol, olmesartan medoxomil
- Where
- Italy
- Volunteers
- 114 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Hypertension
A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)
The purpose of this study is to test the safety and effectiveness of Losartan as compared to Losartan/HCTZ in pediatric patients (6 to 17 years) with high blood pressure.
- Trial name
- NCT00447603
- Testing
- hydrochlorothiazide (+) losartan potassium, losartan potassium
- Volunteers
- 40 people
- Sponsor
- Organon and Co
Hypertension
PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular…
- Trial name
- NCT00936208
- Where
- 120 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 3,184 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
This study is designed to provide long-term safety and efficacy data for the combination doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients.
- Trial name
- NCT00338936
- Testing
- Valsartan + Hydrochlorothiazide
- Volunteers
- 362 people
- Sponsor
- Novartis
Hypertension
The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension
The purpose of this clinical study is to evaluate and compare the efficacy and safety of Fimasartan (60mg / 120mg) with Candesartan(8mg) in patients with mild to moderate hypertension.
- Trial name
- NCT01135212
- Testing
- Fimasartan 60mg, Fimasartan 120mg, Candesartan cilexetil
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, parallel, phase 2 study to explore the dose of HCP1803 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT04959305)
- Testing
- HCP1803-3, RLD2003, RLD2004
- Where
- South Korea
- Volunteers
- 245 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension
This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension.
- Trial name
- NCT00367094
- Testing
- Benazepril plus hydrochlorothiazide
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Novartis
Hypertension
A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension Patients
A multicenter, randomized, double-blind, phase III study to evaluate efficacy and safety of HGP2304 in patients with essential hypertension
- Trial name
- NCT06174766
- Testing
- HGP2304-1, HGP2304-2, RLD2209-1
- Where
- South Korea
- Volunteers
- 356 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension, Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-3" and "BR1019-2" in healthy volunteers
- Trial name
- NCT06636877
- Testing
- BR1019, BR1019-2, BR1019-3
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
This study tested the safety of the combination of aliskiren/amlodipine/hydrochlorothiazide in participants with essential hypertension.
- Trial name
- NCT00667719
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 564 people
- Sponsor
- Novartis
Hypertension
CKD-828 Telmisartan Non-Responder Trial
The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2.5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately…
- Trial name
- NCT01426100
- Testing
- CKD-828 40/2.5mg, CKD-828 40/5mg, Telmisartan 80mg
- Where
- 18 sites in South Korea
- Volunteers
- 183 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension
Study to assess the effect of Telmisartan on diastolic and systolic blood pressure and to establish the effect on patient's quality of life scores.
- Trial name
- MicCAT (NCT02242370)
- Testing
- Low dose of telmisartan, High dose of telmisartan
- Volunteers
- 3,045 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Micardis® in Patients With Essential Hypertension
The aim of this observational study was to supplement the data on efficacy, safety, and tolerability of telmisartan under daily conditions in hospitals
- Trial name
- NCT02187705
- Testing
- Telmisartan tablets
- Volunteers
- 1,688 people
- Sponsor
- Boehringer Ingelheim
Hypertension
RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment
To support physicians in their active management of hypertensive patients. By targeting specific systolic and diastolic blood pressure (BP) figures physicians will closely monitor the BP values and as such will have an…
- Trial name
- RIAT (NCT00258921)
- Volunteers
- 31,870 people
- Sponsor
- Sanofi